Gilead’s twice-yearly lenacapavir nearly doubles PrEP persistence versus daily pill in trial
GILD•Gilead Sciences’ PURPOSE 5 trial found twice-yearly lenacapavir supported more consistent HIV prevention use than daily oral F/TDF over one year, with no infections among lenacapavir recipients and one in the F/TDF group.
1. Trial findings
Gilead Sciences’ PURPOSE 5 trial found that twice-yearly lenacapavir supported more consistent HIV prevention use than daily oral F/TDF over one year. No HIV infections occurred among lenacapavir recipients; one occurred in the F/TDF group. Serious adverse events were uncommon and none were treatment-related, and no lenacapavir recipients stopped treatment because of adverse events.
2. Study presentation
The Phase 2 study was conducted in the United Kingdom and France. Results will be presented at HIV Glasgow 2026.
